Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 380 employees. About 70% of the employees and projects are externally funded. Read more
See introductory video with welcome to the ICR
Trevor Clancy is a cancer bioinformatics scientist with over 20 years of experience in bioinformatics, cancer research and biotechnology. Trevor has focused on integrating multi-omics, tumor–immune biology and AI to generate clinically meaningful insight. He co-founded OncoImmunity (later NEC OncoImmunity following its acquisition by the multinational NEC Corporation) and, as Chief Scientific Officer and leading senior scientist, spearheaded AI-driven personalized cancer immunotherapy projects.
His overarching goal now is to develop robust AI-based tools, such as tumor avatars, that improve cancer prevention, therapy selection and patient outcomes.
Are you a researcher with an innovative idea based on your research that can contribute to solving an important need in society, but need funding to develop the idea further?
The University of Oslo has dedicated NOK 5 million in 2026 for early phase support for innovation projects that have a potential for value creation within all research areas at UiO.
The call is aimed at both commercial and non-commercial projects.
The application deadline is 16 March 2026.
More information here (uio.no)
Scientists from the Department of Radiation Biology report a new strategy to enhance the effectiveness of WEE1 inhibitor–based cancer treatment, published recently in Nucleic Acids Research. The study shows that disrupting transcription termination — the process that properly stops RNA synthesis — significantly increases DNA damage and cancer cell death when combined with the WEE1 inhibitor adavosertib.
A new European collaboration cluster, EARLYSCAN (Early Screening & Hereditary Cancer Awareness Network), has been launched to strengthen prevention and early detection strategies for heritable cancers. The cluster brings together three Horizon Europe–funded projects: SHIELD, DISARM, and PREDI-LYNCH.
The PREDI-LYNCH project is led by Mev Dominguez-Valentin from the Department of Tumor Biology at the Institute for Cancer Research at OUS.
EARLYSCAN operates under the Mission on Cancer priority area “Prevention & early detection – early detection of heritable cancers” and aims to maximise the impact of EU investment by aligning efforts, reducing duplication, and accelerating translation into practice.
Oslo University Hospital hereby announce research awards in the following two catagories for 2026:
Closing date for nominations: March 2nd 2026.
The European Joint Action on Personalised Cancer Medicine officially launched on January 14, bringing together 29 European countries and over 140 partner organisations to advance personalised cancer care across Europe. Coordinated by the Belgian public health institute Sciensano, the project aims to create a sustainable cross-border network to foster innovation, equity, and collaboration in personalised cancer prevention, diagnosis, treatment, follow-up and tertiary prevention.
Oslo University Hospital (OUS) serves as the Norwegian coordinator.
